Phospholipase Cbeta 1b, a target to limit atrial dilatation

磷脂酶 Cbeta 1b，限制心房扩张的目标

• 批准号: nhmrc : 1002328
• 负责人: A/Pr Elizabeth Woodcock
• 金额: $ 36.33万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phospholipase-cbeta-1b-atrial-dilatation/108803
• 关键词: Phospholipase; Cbeta; 1b; target; limit

We have identified a heart specific protein that is involved in perpetuating dilatation of the upper chambers of the heart and thereby contributing to cardiac disease. Inhibitors of this protein provide a suitable target for therapy to limit heart disease. The current studies aim to test such inhibitors in vivo as proof-of-concept that such treatment effectively limits cardiac dysfunction.

我们已经鉴定出一种心脏特异性蛋白质，它参与维持心脏上腔室的扩张，从而导致心脏病。这种蛋白质的抑制剂为限制心脏病的治疗提供了合适的靶点。目前的研究旨在体内测试这种抑制剂，作为这种治疗有效限制心功能障碍的概念验证。